Login / Signup

Nanozymes: a new approach for leukemia therapy.

Wei WangJingyi AnRunze ZhaoXin GengWei JiangXiyun YanBing Jiang
Published in: Journal of materials chemistry. B (2024)
Leukemia is a type of clonal disorder of hematopoietic stem and progenitor cells characterized by bone marrow failure, differentiation arrest, and lineage skewing. Despite leukemia being a complex disease and it being difficult to identify a single driving force, redox homeostasis, the balance between reactive oxygen species (ROS) producers and cellular antioxidant systems, is normally impaired during leukemogenesis. In this context, the modulation of ROS in leukemia cells can be harnessed for therapeutic purposes. Nanozymes are functional nanomaterials with enzyme-like characteristics, which address the intrinsic limitations of natural enzymes and exhibit great potential in synergistic antitumor therapy. Nanozymes possess catalytic activities ( e.g. , peroxidase-like activity, catalase-like activity, superoxide dismutase-like activity, and oxidase-like activity) to regulate ROS levels in vitro and in vivo , making them promising for leukemia therapy. On account of the rapid development of nanozymes recently, their application potentials in leukemia therapy are gradually being explored. To highlight the achievements of nanozymes in the leukemia field, this review summarizes the recent studies of nanozymes with anti-leukemia efficacy and the underlying mechanism. In addition, the challenges and prospects of nanozyme research in leukemia therapy are discussed.
Keyphrases
  • bone marrow
  • acute myeloid leukemia
  • reactive oxygen species
  • mesenchymal stem cells
  • cell death
  • stem cells
  • oxidative stress
  • cell cycle
  • anti inflammatory
  • cell proliferation
  • cell cycle arrest